Sector News

Merck offers EU concessions over $17 bln Sigma-Aldrich buy

May 28, 2015
Life sciences
(Reuters) – German drugmaker Merck has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.
 
Earlier this month, Merck said the European Commission expressed concerns “of a limited nature” over its biggest ever takeover. It submitted concessions on May 22, according to a filing on the EU executive’s website. No details were provided.
 
The EU competition watchdog will now decide by June 15 instead of June 1 whether to approve the takeover.
 
Companies typically offer to sell overlapping assets or provide rivals access to technologies or patents to allay regulatory worries that the merged entity may have an excessive market share. (Reporting by Foo Yun Chee. Editing by Jane Merriman)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).